Introducing HPV screening: Challenges and fallacies

Acta Obstetricia et Gynecologica Scandinavica

Volumn 86, Issue 12, 2007, Pages 1416-1418

  Nieminen, Pekka ^a   Anttila, Ahti ^b  

^a JORVI HOSPITAL   (Finland)

^b FINNISH CANCER REGISTRY   (Finland)

Author keywords

Cervix cancer; Cytology; HPV; Organised; Screening

Indexed keywords

DNA;

CANCER RISK; CANCER SCREENING; CYTOLOGY; HEALTH PROGRAM; HUMAN; MORBIDITY; MORTALITY; NOTE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; EUROPE; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 36248933329     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340701698757     Document Type: Note

References (20)

1. International Agency for Research on Cancer. Cervix cancer screening. IARC Handbooks of Cancer Prevention, Vol 10. Lyon: IARC; 2005:302.
2. Hristova L, Hakama M. Effect of screening for cancer in the Nordic countries on deaths, costs and quality of life up to the year 2017. Acta Oncol. 1997;Suppl 9:1-60.
3. Sigurdsson K. The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand. 1999;78:478-85.
4. Magnus K, Langmark F, Andersen A. Mass screening for cervical cancer in Ostfold county of Norway 1959-77. Int J Cancer. 1987;39:311-6.
5. Anttila A, Ronco G, Clifford G, Bray F, Hakama M, Arbyn M, et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer. 2004;91:935-41.
6. Siebert U, Sroczynski G, Hillemanns P, Engel J, Stabenow R, Stegmaier C, et al. The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. Eur J Public Health. 2006;16:185-92.
7. Breitenecker G, Dinges HP, Regitnig P, Wiener H, Vutuc C. Cytopathology in Austria. Cytopathology. 2004;15:113-8.
8. Arbyn M, Sasieni P, Meijer CLM, Clavel C, Koliopoulos G, Dillner J. Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 24;Suppl 31:S3/78-89.
9. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095-101.
10. Nieminen P, Vuorma S, Viikki M, Hakama M, Anttila A. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer. BJOG. 2004;111:842-8.
11. International Agency for Research on Cancer. IARC Working Group on Cervical Cancer Screening and the UICC Project Group on the Evaluation of Screening Programmes for Cancer. IARC Science Publication; 1986.
12. Anttila A, Nieminen P, Kotaniemi L, Hakama M. A multi-arm randomised trial on new technologies in cervical cancer screening. [A study design]. BMC Public Health. 2006;6:252-5.
13. World Health Organisation. Comprehensive cervical cancer control: a guide to essential practice. Geneva: WHO; 2007.
14. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. A routine cervical screening with test for high-risk HPV types: first year results of a randomised multi-arm trial. Br J Cancer. 2005;93:862-7.
15. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intra-epithelial or early invasive cervical lesions: a systematic review and meta-analysis of the literature. Lancet. 2006;367:489-98.
16. Jakobsson M, Gissler M, Sainio S, Paavonen J, Tapper AM. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet Gynecol. 2007;109:309-13.
17. Bosch FX, editor. HPV vaccines and screening in the prevention of cervical cancer. Vaccine. 2006;24 Suppl 3:261.
18. Koutsky LA; the FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27.
19. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369:1861-8.
20. Paavonen J. Efficacy of a human papillomavirus-16/18 L1 virus-like particle (VLP) AS04 vaccine: a phase III randomized, controlled trial in young women. Lancet. 2007;369:2161-70.